GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of week 19 check-in — 9kg down, early fullness manageable, one thing confusing me — 41 comments in the full submission. View in context.
8.3k
c/retatrutide·submitted 2 years ago by u/incretin_ivy

week 19 check-in — 9kg down, early fullness manageable, one thing confusing me

Trial Databranch of 7 comments

week 19 check-in — 9kg down, early fullness manageable, one thing confusing me, logged the same way every week so the comparison is at least internally fair. The numbers the title promised, since a headline without them is worthless: week 19 and 9kg. Everything below is context for those. Kept a log specifically…

Read the full submission and all 41 comments →

This branch

7 comments, started 2 years ago
u/zeynep_mbeki192 points·2 years ago

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

replysharereportpermalink
u/sofia_wikstrom57 points·2 years ago

Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.

replysharereportpermalink
u/two_mil_or_one48 points·2 years ago

This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.

replysharereportpermalink
u/incretin_ivyOPpharmacology42 points·2 years ago

dose escalation in the trials was slow for a reason

replysharereportpermalink
u/incretin_ivypharmacology29 points·2 years ago

That is body weight change, not fat mass. The trials report the first and people quote it as the second.

replysharereportpermalink
u/yusuf_ramos49 points·2 years ago

Are you comparing against phase 3 numbers for something else? They are not comparable.

replysharereportpermalink
u/lina_bruun-7 points·2 years ago

Stopped at a low step because there was no reason to go further and no data to tell me what further would do.

replysharereportpermalink

← back to the whole thread

About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.